Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Horwitz SM, et al. Among authors: saunders me. Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6. Blood. 2012. PMID: 22394596 Free article. Clinical Trial.
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. O'Connor OA, et al. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652067 Free PMC article. Clinical Trial.
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM. Azzoli CG, et al. J Thorac Oncol. 2011 Nov;6(11):1915-22. doi: 10.1097/JTO.0b013e31822adb19. J Thorac Oncol. 2011. PMID: 21841501 Free article. Clinical Trial.
Molecular and niche modeling approaches to identify potential amplifying hosts for an emerging tick-borne pathogen, Rickettsia rickettsii subsp. californica, the causative agent of Pacific Coast tick fever.
Mai V, Boria RA, Padgett K, Koo MS, Saunders MEM, Billeter S, Asin J, Shooter S, Zambrano M, Karpathy S, Paddock CD, Swei A. Mai V, et al. Among authors: saunders mem. J Med Entomol. 2024 Dec 17:tjae147. doi: 10.1093/jme/tjae147. Online ahead of print. J Med Entomol. 2024. PMID: 39688497
Perspectives from federal and state public health departments on their participation in and the utility of Ixodes scapularis (Acari: Ixodidae) and Ixodes pacificus tick and tick-borne pathogen surveillance in the United States.
Eisen RJ, Foster E, Kjemtrup A, Saunders MEM, Brown J, Green L, Cervantes K, Prusinski MA, White J, Barbarin AM, Williams C, Kwit N, Bernick J, Gaines D, Dykstra E, Oltean HN, Dotseth E, Lee X, Osborn R. Eisen RJ, et al. Among authors: saunders mem. J Med Entomol. 2024 Dec 9:tjae149. doi: 10.1093/jme/tjae149. Online ahead of print. J Med Entomol. 2024. PMID: 39657826
Newly Recognized Spotted Fever Group Rickettsia as Cause of Severe Rocky Mountain Spotted Fever-Like Illness, Northern California, USA.
Probert WS, Haw MP, Nichol AC, Glaser CA, Park SY, Campbell LE, Trivedi KK, Romo H, Saunders MEM, Kjemtrup AM, Padgett KA, Hacker JK. Probert WS, et al. Among authors: saunders mem. Emerg Infect Dis. 2024 Jul;30(7):1344-1351. doi: 10.3201/eid3007.231771. Epub 2024 May 30. Emerg Infect Dis. 2024. PMID: 38816345 Free PMC article.
CaSSiDI: novel single-cell "Cluster Similarity Scoring and Distinction Index" reveals critical functions for PirB and context-dependent Cebpb repression.
Nechanitzky R, Ramachandran P, Nechanitzky D, Li WY, Wakeham AC, Haight J, Saunders ME, Epelman S, Mak TW. Nechanitzky R, et al. Among authors: saunders me. Cell Death Differ. 2024 Mar;31(3):265-279. doi: 10.1038/s41418-024-01268-8. Epub 2024 Feb 21. Cell Death Differ. 2024. PMID: 38383888 Free PMC article.
51 results